ATE553098T1 - Verfahren zur herstellung von rosuvastatin- calcium - Google Patents

Verfahren zur herstellung von rosuvastatin- calcium

Info

Publication number
ATE553098T1
ATE553098T1 AT08702369T AT08702369T ATE553098T1 AT E553098 T1 ATE553098 T1 AT E553098T1 AT 08702369 T AT08702369 T AT 08702369T AT 08702369 T AT08702369 T AT 08702369T AT E553098 T1 ATE553098 T1 AT E553098T1
Authority
AT
Austria
Prior art keywords
rosuvastatin calcium
producing rosuvastatin
producing
calcium
dihydroxyhept
Prior art date
Application number
AT08702369T
Other languages
English (en)
Inventor
Ramesh Dandala
Sambhu Prasad Sarma Mallela
Sukumar Nandi
Gangadhar Bhima Shankar Nangi
Sunil Kumar Buridipadu
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Application granted granted Critical
Publication of ATE553098T1 publication Critical patent/ATE553098T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
AT08702369T 2007-02-08 2008-02-04 Verfahren zur herstellung von rosuvastatin- calcium ATE553098T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN277CH2007 2007-02-08
IN1121CH2007 2007-05-29
PCT/IB2008/000290 WO2008096257A1 (en) 2007-02-08 2008-02-04 An improved process for preparation of rosuvastatin calcium

Publications (1)

Publication Number Publication Date
ATE553098T1 true ATE553098T1 (de) 2012-04-15

Family

ID=39323006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08702369T ATE553098T1 (de) 2007-02-08 2008-02-04 Verfahren zur herstellung von rosuvastatin- calcium

Country Status (7)

Country Link
US (1) US8212035B2 (de)
EP (1) EP2125754B1 (de)
AT (1) ATE553098T1 (de)
AU (1) AU2008212622B2 (de)
CA (1) CA2677809A1 (de)
ES (1) ES2385623T3 (de)
WO (1) WO2008096257A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP2062903A1 (de) 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin-Zwischenprodukte und Verfahren zur Herstellung von Statine
WO2010071595A1 (en) * 2008-12-19 2010-06-24 Sekab Biofuels & Chemicals Ab Denaturant-containing, ethanol-based liquid
WO2015030001A1 (ja) 2013-08-30 2015-03-05 日産化学工業株式会社 光学活性５－ヒドロキシ－３－ケトエステル類の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
US20050222415A1 (en) 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004052867A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
US20070191318A1 (en) 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1797046A2 (de) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Neue verfahren zur herstellung von amorphem rosuvastatincalcium und neue polymorphe form von rosuvastatinnatrium
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US20070037979A1 (en) 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2006100689A1 (en) 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) * 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
WO2006136408A2 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
EP2508514B1 (de) 2005-06-24 2017-10-18 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von amorphem Rosuvastatincalcium frei von Verunreinigungen
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8354530B2 (en) 2005-07-28 2013-01-15 Lek Pharmaceuticals d. d Process for the synthesis of rosuvastatin calcium
WO2007022366A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Rosuvastatin calcium with a low salt by-product content
KR20090113920A (ko) 2005-10-03 2009-11-02 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 부분입체 이성질체 정제
WO2007099561A1 (en) 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (de) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Verfahren zur Herstellung des Methylesters von Rosuvastatin
HU230637B1 (hu) 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására

Also Published As

Publication number Publication date
US8212035B2 (en) 2012-07-03
ES2385623T3 (es) 2012-07-27
AU2008212622B2 (en) 2011-01-27
EP2125754B1 (de) 2012-04-11
WO2008096257A1 (en) 2008-08-14
CA2677809A1 (en) 2008-08-14
US20090312547A1 (en) 2009-12-17
EP2125754A1 (de) 2009-12-02
AU2008212622A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
DE60132178D1 (de) CRISTALLINSALZE VON 7-i4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL -(3R,5S)-3,5-DIHYDROXYHEPT-6-ENSÄURE
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
MX2017011330A (es) Proceso quimico para preparar derivados de pirimidina y sus intermediarios.
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
MX342874B (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
NZ610765A (en) Method for the preparation of high-purity pharmaceutical intermediates
DE602004004679D1 (de) Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure
NZ611072A (en) Method for preparing rosuvastatin salts
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt